6540-25-6

Upstream product

• 65-85-0 benzoic acid 

Downstream Products

• 177216-91-0 [Mn(CO)4(SeCO₂C₆H₅)]2 
• 1486479-60-0 C₂₂H₂₄O₅ 
• 3393-96-2 p-nitrobenzanilide 
• 16091-26-2 N-Benzoyl-m-phenylendiamin 
• 17625-83-1 N-(4-aminophenyl)benzamide 
• 4771-08-8 N-(3-nitrophenyl)benzamide 
• 16709-58-3 2-oxo-2H-chromen-4-yl benzoate 
• 114124-22-0 4-O-benzoyl-3:1,2-O-<(R)-1-ethanyl-2-ylidene>-5,6-O-(S)-ethylidene-D-mannitol 
• 78137-55-0 1-<<2-<(phenoxycarbonyl)oxy>ethoxy>methyl>-N⁴-acetylcytosine 
• 117633-04-2 Bis-bicyclo[1.1.1]pent-1-yl-phenyl-methanol 
• 117633-11-1 Benzoic acid bicyclo[1.1.1]pent-1-yl ester 

Relevant academic research and scientific papers

Aza-acridine compound and preparation method and application thereof

The invention discloses a method for efficiently preparing an aza-acridine compound. The structural formula of the aza-acridine compound is shown as a formula I; the preparation method comprises the following steps: adding a 2-aminoquinoline-3-methanamide compound and a solvent under an air condition, and heating to reaction temperature; after the reaction is ended, separating and purifying to obtain multisubstituted acridine derivatives shown as the following formula, wherein the reaction temperature is 100 to 200DEG C, and the reaction time is 1 to 24 hours. A synthetic method of the aza-acridine compound, disclosed by the invention, has the advantages of scientificity, reasonability, simple and easily-operated synthesis process and high synthetic yield; a product is easy to purify. The invention also relates to the aza-acridine compound which can be used for inhibiting EGFR (Epidermal Growth Factor Receptor) and SrC, a preparation method of the aza-acridine compound, activity of a drug containing the aza-acridine compound and the application of the drug. The compound is shown in a formula II and can be used for preparing an EGFR and SrC activity inhibitor and a disease treatment medicine activated and mediated by the EGFR and the SrC.